Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 6 min ago
PreprintCC BYmedRxiv

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

  1. 1Department of Orthopedic Rehabilitation, Taihe Hospital, Hubei University of Medicine, Shiyan, China

Abstract

Background: Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods: We analysed genome-wide data on seven disorders from FinnGen and UK Biobank (over 900,000 participants) by genomic structural equation modelling, tested five endocrine and metabolic exposures by Mendelian randomisation, mapped heritability onto 110,020 connective-tissue cells, and pooled serious adverse events from 210 placebo-controlled trials of incretin receptor agonists (134,138 participants). Findings: The disorders formed two replicated heritable axes: tenosynovial (carpal tunnel syndrome, trigger finger, de Quervain tenosynovitis; 61 loci) and fibro-capsular (frozen shoulder, Dupuytren's disease, plantar fascial disorder; 42 loci). Each SD higher genetically predicted body mass index increased the odds of carpal tunnel syndrome (odds ratio [OR] 1.67, 95% CI 1.47-1.89; P = 6.9 x 10^-16) and decreased those of Dupuytren's disease (0.57, 0.46-0.71; P = 8.7 x 10^-7), whose heritability concentrated in lesional POSTN+ fibroblasts. Incretin receptor agonists increased serious fibro-capsular events (Peto OR 3.88, 1.83-8.25; P = 4.1 x 10^-4), including frozen shoulder (4.16, 1.50-11.54) and Dupuytren's disease (3.58, 1.17-10.93), but not tenosynovial events (1.02, 0.60-1.75). Interpretation: Hand and shoulder soft-tissue disease comprises two genetically distinct axes with opposite responses to adiposity. It identifies frozen shoulder and Dupuytren's disease as musculoskeletal pharmacovigilance targets for the millions receiving incretin receptor agonists. Funding: Health Commission of Hubei Province (WJ2023F086) and Department of Science and Technology of Hubei Province (2024BCB059).

Related

  1. Divergent associations between adiposity and hernia subtypes in European populations: A Mendelian randomization study.
    Yao Lu, Huiping Yuan, Ke Zhang +1
    MedicinePeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  2. Divergent genetic mediator signatures of adiposity-related metabolic liabilities and coronary artery disease.
    J. A. SIMON CAMPOS, H. Laviada-Molina, P. CAMPOS CORZO +1
    medRxivPreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
  3. Glycemia reprograms substrate transport and shapes divergent stress responses in differentiating H9c2 cells
    Sofia Passaponti, Asia Iserani, Roberta Romagnoli +5
    Cell stressPeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  4. Comparable Acute Antidepressant-like Effects of Two Subanesthetic Ketamine Doses Are Associated with Divergent Region-Specific Molecular Responses After Adolescent Chronic Stress
    Ana Zivanovic, Iva Lukic, Emilija Glavonic +4
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  5. Species-specific liver microtissues reveal divergent adverse responses to fialuridine treatment.
    Maria Vittoria Colombo, Agnieszka Pawlowska, Friederike Wenz +10
    Cell biology and toxicologyPeer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMCPMC
BibTeX
@misc{xu2026genetic,
  title = {{Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study}},
  author = {Z. Xu and J. Cheng and X. Chen and J. Luo and X. Zhu and X. Guo},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.27.26366575},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.27.26366575v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
AU  - Z. Xu
AU  - J. Cheng
AU  - X. Chen
AU  - J. Luo
AU  - X. Zhu
AU  - X. Guo
PY  - 2026
DA  - 2026/10/27
PB  - medRxiv
DO  - 10.64898/2026.10.27.26366575
UR  - https://www.medrxiv.org/content/10.64898/2026.10.27.26366575v1
AB  - Background: Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods: We analysed genome-wide data on seven disorders from FinnGen and UK Biobank (over 900,000 participants) by genomic structural equation modelling, tested five endocrine and metabolic exposures by Mendelian randomisation, mapped heritability onto 110,020 connective-tissue cells, and pooled serious adverse events from 210 placebo-controlled trials of incretin receptor agonists (134,138 participants). Findings: The disorders formed two replicated heritable axes: tenosynovial (carpal tunnel syndrome, trigger finger, de Quervain tenosynovitis; 61 loci) and fibro-capsular (frozen shoulder, Dupuytren's disease, plantar fascial disorder; 42 loci). Each SD higher genetically predicted body mass index increased the odds of carpal tunnel syndrome (odds ratio [OR] 1.67, 95% CI 1.47-1.89; P = 6.9 x 10^-16) and decreased those of Dupuytren's disease (0.57, 0.46-0.71; P = 8.7 x 10^-7), whose heritability concentrated in lesional POSTN+ fibroblasts. Incretin receptor agonists increased serious fibro-capsular events (Peto OR 3.88, 1.83-8.25; P = 4.1 x 10^-4), including frozen shoulder (4.16, 1.50-11.54) and Dupuytren's disease (3.58, 1.17-10.93), but not tenosynovial events (1.02, 0.60-1.75). Interpretation: Hand and shoulder soft-tissue disease comprises two genetically distinct axes with opposite responses to adiposity. It identifies frozen shoulder and Dupuytren's disease as musculoskeletal pharmacovigilance targets for the millions receiving incretin receptor agonists. Funding: Health Commission of Hubei Province (WJ2023F086) and Department of Science and Technology of Hubei Province (2024BCB059).
ER  -